Current Neuro-Oncology

Volume 22 Number 5
15 March 2020

Home > Publications > Current Neuro-Oncology > Volume 22, Year 2020 > Number 5, 15 March

Luo Y, Zeng L, Xie XQ, Wang F, Liu YZ, Kang JB, Li XF, Wu DB, Qu BL.
H3K27M mutant diffuse midline glioma: a case report.
Eur Rev Med Pharmacol Sci. 2020 Mar;24(5):2579-2584. doi: 10.26355/eurrev_202003_20527. PMID: 32196609. Case report. ˍ

Khurana R, Rath S, Singh HB, Rastogi M, Nanda SS, Chauhan A, Kaif M, Hussain N.
Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation.
Asian Pac J Cancer Prev. 2020 Mar 1, 2020;21(3):755-760. doi: 10.31557/APJCP.2020.21.3.755. PMID: 32212804. Observational study. ˍ

El Husseini K, Marguet F, Lamy A, Magne N, Fontanilles M.
Major response to temozolomide as first-line treatment for newly-diagnosed DDR2-mutated glioblastoma: A case report.
Rev Neurol (Paris). 2020 Mar 2, 2020;176(5):402-404. doi: 10.1016/j.neurol.2019.09.007. PMID: 32139182. Case report. ˍ

Tunthanathip T, Ratanalert S, Sae-Heng S, Oearsakul T, Sakaruncchai I, Kaewborisutsakul A, Chotsampancharoen T, Intusoma U, Kitkhuandee A, Vaniyapong T.
Prognostic Factors and Nomogram Predicting Survival in Diffuse Astrocytoma.
J Neurosci Rural Pract. 2020 Mar 3, 2020;11(1):135-143. doi: 10.1055/s-0039-3403446. PMID: 32140017. Observational study. ˍ

Akbari H, Rathore S, Bakas S, Nasrallah MP, Shukla G, Mamourian E, Rozycki M, Bagley SJ, Rudie JD, Flanders AE, Dicker AP, Desai AS, O'Rourke DM, Brem S, Lustig R, Mohan S, Wolf RL, Bilello M, Martinez-Lage M, Davatzikos C.
Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma.
Cancer. 2020 Mar 4, 2020;126(11):2625-2636. doi: 10.1002/cncr.32790. PMID: 32129893. Observational study. ˍ

Yamashiro K, Nakao K, Ohba S, Hirose Y.
Human Glioma Cells Acquire Temozolomide Resistance After Repeated Drug Exposure Via DNA Mismatch Repair Dysfunction.
Anticancer Res. 2020 Mar 4, 2020;40(3):1315-1323. doi: 10.21873/anticanres.14073. PMID: 32132028. Laboratory investigation. ˍ

Fortin J, Tian R, Zarrabi I, Hill G, Williams E, Sanchez-Duffhues G, Thorikay M, Ramachandran P, Siddaway R, Wong JF, Wu A, Apuzzo LN, Haight J, You-Ten A, Snow BE, Wakeham A, Goldhamer DJ, Schramek D, Bullock AN, Dijke PT, Hawkins C, Mak TW.
Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas.
Cancer Cell. 2020 Mar 5, 2020;37(3):308-323.e12. doi: 10.1016/j.ccell.2020.02.002. PMID: 32142668. Laboratory investigation. ˍ

Liu CJ, Schaettler M, Blaha DT, Bowman-Kirigin JA, Kobayashi DK, Livingstone AJ, Bender D, Miller CA, Kranz DM, Johanns TM, Dunn GP.
Treatment of an Aggressive Orthotopic Murine Glioblastoma Model with Combination Checkpoint Blockade and a Multivalent Neoantigen Vaccine.
Neuro Oncol. 2020 Mar 5, 2020;22(9):1276-1288. doi: 10.1093/neuonc/noaa050. PMID: 32133512. Laboratory investigation. ˍ

Meazza C, Schiavello E, Biassoni V, Podda M, Barteselli C, Barretta F, Gattuso G, Terenziani M, Ferrari A, Spreafico F, Luksch R, Casanova M, Chiaravalli S, Puma N, Bergamaschi L, Massimino M.
Cancer treatment in disabled children.
Eur J Pediatr. 2020 Mar 5, 2020;179(9):1353-1360. doi: 10.1007/s00431-020-03607-6. PMID: 32140854. Observational study. ˍ

Urup T, Gillberg L, Kaastrup K, Lü MJS, Michaelsen SR, Andrée Larsen V, Christensen IJ, Broholm H, Lassen U, Grønbaek K, Poulsen HS.
Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma.
Mol Oncol. 2020 Mar 5, 2020;14(5):964-973. doi: 10.1002/1878-0261.12660. PMID: 32133779. Laboratory investigation. ˍ

White-Gilbertson S, Lu P, Jones CM, Chiodini S, Hurley D, Das A, Delaney JR, Norris JS, Voelkel-Johnson C.
Tamoxifen is a candidate first-in-class inhibitor of acid ceramidase that reduces amitotic division in polyploid giant cancer cells-Unrecognized players in tumorigenesis.
Cancer Med. 2020 Mar 5, 2020;9(9):3142-3152. doi: 10.1002/cam4.2960. PMID: 32135040. Laboratory investigation. ˍ

Wick A, Desjardins A, Suarez C, Forsyth P, Gueorguieva I, Burkholder T, Cleverly AL, Estrem ST, Wang S, Lahn MM, Guba SC, Capper D, Rodon J.
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Invest New Drugs. 2020 Mar 5, 2020;38(5):1570-1579. doi: 10.1007/s10637-020-00910-9. PMID: 32140889. Interventional study. ˍ

Djurovic Z, Jovanovic V, Obrenovic R, Djurovic B, Soldatovic I, Vranic A, Jakovljevic V, Djuric D, Zivkovic V.
The importance of the blood levels of homocysteine, folate and vitamin B12 in patients with primary malignant brain tumors.
J BUON. 2020 [Mar 6], 2020 Nov-Dec;25(6):2600-2607[pdf]
ˍ. PMID: 33455102. Observational study. ˍ

Park JE, Kim HS, Jo Y, Yoo RE, Choi SH, Nam SJ, Kim JH.
Radiomics prognostication model in glioblastoma using diffusion- and perfusion-weighted MRI.
Sci Rep. 2020 Mar 6, 2020;10(1):4250. doi: 10.1038/s41598-020-61178-w. PMID: 32144360. Observational study. ˍ

Chan J, Jayamanne D, Wheeler H, Khasraw M, Wong M, Kastelan M, Guo L, Back M.
The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade glioma.
Clin Transl Radiat Oncol. 2020 Mar 9, 2020;22:33-39. doi: 10.1016/j.ctro.2020.03.005. PMID: 32195378. Observational study. ˍ

Khatua S, Cooper LJN, Sandberg DI, Ketonen L, Johnson JM, Rytting ME, Liu DD, Meador H, Trikha P, Nakkula RJ, Behbehani GK, Ragoonanan D, Gupta S, Kotrotsou A, Idris T, Shpall EJ, Rezvani K, Colen R, Zaky W, Lee DA, Gopalakrishnan V.
Phase I study of intraventricular infusions of autologous ex-vivo-expanded NK cells in children with recurrent medulloblastoma and ependymoma.
Neuro Oncol. 2020 Mar 10, 2020;22(8):1214-1225. doi: 10.1093/neuonc/noaa047. PMID: 32152626. Interventional study. ˍ

Lee EQ, Zhang P, Wen PY, Gerstner ER, Reardon DA, Aldape KD, deGroot JF, Pan E, Raizer JJ, Kim LJ, Chmura SJ, Robins HI, Connelly JM, Battiste JD, Villano JL, Wagle N, Merrell RT, Wendland MM, Mehta MP.
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.
Cancer. 2020 Mar 10, 2020;126(12):2821-2828. doi: 10.1002/cncr.32811. PMID: 32154928. Interventional study. ˍ

Niu X, Wang T, Zhou X, Yang Y, Wang X, Zhang H, Chen N, Yue Q, Wang F, Zhang Y, Liu Y, Mao Q.
Surgical treatment and survival outcome of patients with adult thalamic glioma: a single institution experience of 8 years.
J Neurooncol. 2020 Mar 10, 2020;147(2):377-386. doi: 10.1007/s11060-020-03430-x. PMID: 32157551. Observational study. ˍ

Park JE, Kim HS, Park SY, Jung SC, Kim JH, Heo HY.
Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Radiology. 2020 Mar 10, 2020;295(2):397-406. doi: 10.1148/radiol.2020191376. PMID: 32154775. Observational study. ˍ

Rudnick JD, Sarmiento JM, Uy B, Nuno M, Wheeler CJ, Mazer MJ, Wang H, Hu JL, Chu RM, Phuphanich S, Black KL, Yu JS.
A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
J Clin Neurosci. 2020 Mar 10, 2020;74:187-193. doi: 10.1016/j.jocn.2020.03.006. PMID: 32169363. Interventional study. ˍ

Eberhart C.
Astrocytes - New Stars In The Medulloblastoma Firmament.
Neuro Oncol. 2020 Mar 11, 2020;22(5):587-589. doi: 10.1093/neuonc/noaa057. PMID: 32157298. Comment. ˍ
Refers to: Liu H et al., Necroptotic astrocytes contribute to maintaining stemness of disseminated medulloblastoma through CCL2 secretion. Neuro Oncol. 2019 Nov 15, 2020;22(5):625-638. doi: 10.1093/neuonc/noz214. PMID: 31729527. Laboratory investigation. ˍ

Jin MC, Liu EK, Shi S, Gibbs IC, Thomas R, Recht L, Soltys SG, Pollom EL, Chang SD, Hayden Gephart M, Nagpal S, Li G.
Evaluating Surgical Resection Extent and Adjuvant Therapy in the Management of Gliosarcoma.
Front Oncol. 2020 Mar 11, 2020;10:337. doi: 10.3389/fonc.2020.00337. PMID: 32219069. Observational study. ˍ

Brown NF, Ng SM, Brooks C, Coutts T, Holmes J, Roberts C, Elhussein L, Hoskin P, Maughan T, Blagden S, Mulholland P.
A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Gliotrial protocol.
BMC Cancer. 2020 Mar 12, 2020;20(1):198. doi: 10.1186/s12885-020-6624-y. PMID: 32164579. Protocol. ˍ

Meel MH, de Gooijer MC, Metselaar DS, Sewing ACP, Zwaan K, Waranecki P, Breur M, Buil LCM, Lagerweij T, Wedekind LE, Twisk JWR, Koster J, Hashizume R, Raabe EH, Montero-Carcaboso A, Bugiani M, Phoenix TN, van Tellingen O, van Vuurden DG, Kaspers GJL, Hulleman E.
Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma.
Clin Cancer Res. 2020 Mar 12, 2020;26(13):3319-3332. doi: 10.1158/1078-0432.CCR-19-3538. PMID: 32165429. Laboratory investigation. ˍ

Perez-Roman RJ, Hubbard ZS, Brusko GD, Starke RM.
A case of primary central nervous system lymphoma presenting as a shunt complication.
Br J Neurosurg. 2020 Mar 12, 2020:1-4. doi: 10.1080/02688697.2020.1735300. PMID: 32164443. Case report. ˍ


Wu X, Li Y, Glastonbury CM, Cha S.
Involvement of the Olfactory Apparatus by Gliomas.
AJNR Am J Neuroradiol. 2020 Mar 12, 2020;41(4):712-717. doi: 10.3174/ajnr.A6471. PMID: 32165363. Case report. ˍ

Kong L, Wu J, Gao J, Qiu X, Yang J, Hu J, Hu W, Mao Y, Lu JJ.
Particle radiation therapy in the management of malignant glioma: Early experience at the Shanghai Proton and Heavy Ion Center.
Cancer. 2020 Mar 13, 2020;126(12):2802-2810. doi: 10.1002/cncr.32828. PMID: 32167589. Observational study. ˍ

Mathur R, Zhang Y, Grimmer MR, Hong C, Zhang M, Bollam S, Petrecca K, Clarke J, Berger MS, Phillips JJ, Oberheim-Bush NA, Molinaro AM, Chang SM, Costello JF.
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.
Neuro Oncol. 2020 Mar 13, 2020;22(11):1580-1590. doi: 10.1093/neuonc/noaa059. PMID: 32166314. Laboratory investigation. ˍ

Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR.
A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma.
Neuro Oncol. 2020 Mar 13, 2020;22(10):1505-1515. doi: 10.1093/neuonc/noaa062. PMID: 32166308. Interventional study. ˍ

Jeanmougin M, Håvik AB, Cekaite L, Brandal P, Sveen A, Meling TR, Ågesen TH, Scheie D, Heim S, Lothe RA, Lind GE.
Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
Mol Oncol. 2020 Mar 14, 2020;14(5):1016-1027. doi: 10.1002/1878-0261.12668. PMID: 32171051. Laboratory investigation. ˍ

Szychot E, Youssef A, Ganeshan B, Endozo R, Hyare H, Gains J, Mankad K, Shankar A.
Predicting Outcome In Childhood Diffuse Midline Gliomas Using Magnetic Resonance Imaging Based Texture Analysis.
J Neuroradiol. 2020 Mar 14, 2021;48(4):243-247. doi: 10.1016/j.neurad.2020.02.005. PMID: 32184119. Observational study. ˍ